-transparent.png){kind=logo}
The agonistic analogues of luteinizing hormone releasing hormone decrease biochemical findings and clinical signs of gonadotropin-dependent precocious puberty. We tested a new analogue, nafarelin acetate, in 15 girls with gonadotropin-dependent precocious puberty. The hydrophobic nature and potency of this compound allow it to be administered by intranasal inhalation. Laboratory assessment of vaginal cytology, estradiol and urinary gonadotropin levels, and growth velocity revealed that nafarelin acetate 800 to 1200 micrograms/day diminished these values during a 6-month treatment period. These results suggest gonadotropin-dependent precocious puberty in girls can be treated with intranasal administration of nafarelin acetate.
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
March 1988,
Experimental and clinical endocrinology,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
October 1989,
Journal of steroid biochemistry,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
November 1988,
Bulletin de l'Academie nationale de medecine,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
November 1987,
European journal of pediatrics,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
June 1985,
Clinical endocrinology,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
October 1989,
Australian paediatric journal,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
January 1988,
Gynakologische Rundschau,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
January 1989,
Medicina,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
October 2007,
Journal of the Formosan Medical Association = Taiwan yi zhi,
T H Lin, and
M E LePage, and
M Henzl, and
J L Kirkland
January 1995,
Acta neurochirurgica,
